Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials

PSYCHONEUROENDOCRINOLOGY

卷:94

Review

Moulton, Calum D.¹  Hopkins, Christopher W. P.²  Ismail, Khalida^1,4  Stahl, Daniel³ 

[1] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, London SE5 9RJ, England

[2] Prospect Pk Hosp, Berkshire Healthcare NHS Fdn Trust, Reading, Berks, England

[3] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Biostat & Hlth Informat, London SE5 9RJ, England

[4] Kings Hlth Partners Acad Hlth Sci Ctr, Inst Diabet Obes & Endocrinol, London, England

关键词: Depressive symptoms;    Diabetes;    Repositioning;    Systematic review;    Meta-analysis;    Meta-regression;    Inflammation;    Insulin resistance;    Pioglitazone;    Metformin;   

DOI  :  10.1016/j.psyneuen.2018.05.010

来源: Elsevier

【 摘 要 】

Depression is a common comorbidity in diabetes but conventional antidepressant treatments do not consistently improve outcomes. We tested whether established diabetes treatments can also improve depressive symptoms and examined biological correlates of response. We performed a multi-database systematic search of all clinical trials, which measured the effect of licensed diabetes treatments on depressive symptoms using a validated questionnaire. Results of randomised controlled trials (RCT's) were pooled for meta-analysis. Data were also collected on insulin resistance (HOMA-IR), C-reactive protein (CRP) and fasting blood glucose (FBG) as correlates of response. Nineteen studies (n = 3369 patients) were included in the qualitative synthesis, 9 testing thiazolidenediones, 5 metformin, 2 thiazolidenediones against metformin, 2 incretin-based therapies and 1 insulin. Most studies were of good quality. In random-effects meta-analysis of RCT's, pioglitazone improved depressive symptoms compared to controls (pooled effect size = -0.68 (95% C.I -1.12 to -0.24), p = .003, N-studies = 8, I-2 = 83.2%). Conversely, metformin was comparable to controls overall (pooled effect size = + 0.32 (95% C.I. -0.23 to 0.88), p = .25, N-studies = 6, I-2 = 94.2%), although inferior to active controls (pooled effect size = + 1.32 (95% C.I. 0.31-2.34), p < 0.001, N-studies = 3, 12 = 90.1%). In random-effects meta regression, female sex (beta = 0.023, (95% C.I. -0.041 to -0.0041), p = .016, N-studies = 8) predicted reduction in depressive symptoms with pioglitazone, but baseline HOMA-IR, FBG and severity of depressive symptoms did not. In conclusion, pioglitazone was associated with improvement in depressive symptoms, an effect more marked in women and poorly explained by effects on glycaemia and insulin resistance. Metformin had no consistent benefit on depressive symptoms. Further mechanistc trials of diabetes treatments as potential antidepressants are needed, stratified by sex and including serial measures of innate inflammation.

【 授权许可】

Free